Kleenex tissue maker Kimberly-Clark's quarterly sales jump on strong demand

Kimberly-Clark (KMB) reported strong second-quarter results, with adjusted EPS of $1.92 significantly surpassing analyst estimates of $1.67, driven by a 3.9% increase in organic sales from robust volume growth in key brands like Huggies and Kleenex. This performance, despite a 1.6% decline in net sales from continuing operations, reflects the company's strategic portfolio diversification and cost-control initiatives, including the $3.4 billion sale of its international tissue business. KMB shares rose premarket, and the company now projects improved low-to-mid single-digit adjusted EPS growth for 2025, signaling a more optimistic outlook.

Analysis

Kimberly-Clark (KMB) reported a strong second quarter, highlighted by an adjusted EPS of $1.92 that significantly beat analyst consensus of $1.67. This outperformance was driven by a 3.9% increase in organic sales, which is notable as it was fueled by a robust 5% growth in overall volumes, successfully offsetting a 1.2% decline in prices. This dynamic suggests resilient consumer demand for core brands like Huggies and Kleenex, even as pricing power softened. While net sales from continuing operations saw a slight year-over-year decline of 1.6%, the company's strategic initiatives, such as portfolio diversification across price tiers and cost controls, appear to be yielding positive results. A key strategic development is the $3.4 billion deal to divest a majority stake in its international tissue business, a move aimed at streamlining operations and focusing on higher-growth segments. Reflecting this operational strength and strategic repositioning, management has upgraded its 2025 adjusted EPS growth forecast to a low- to mid-single-digit rate, a marked improvement from the previous flat-to-positive guidance.

Key Decisions for Investors

• The significant earnings beat and upgraded 2025 guidance provide a bullish signal on the effectiveness of KMB's cost management and strategic focus, warranting a positive reassessment of the stock's near-term prospects.
• Investors should monitor the volume versus price dynamic closely; continued strong volume growth is critical to sustaining momentum, especially if pricing remains soft in the competitive consumer staples environment.
• The pending divestiture of the international tissue business to Suzano is a key long-term catalyst for margin improvement, but its financial impact will not be fully realized until the deal closes in mid-2026.
• Consider the company's ability to maintain market share against rivals like Procter & Gamble, as the success of its multi-tiered product strategy is a core component of the investment thesis.